CSL Statutory Accounts for the Half Year Ended 31 Dec 2022
Filed with ASX · · 28 pages · English
Earlier from CSL
- CSL Half Year Results Announcement & Investor Presentation
- Appointment of CSLs next CEO & Managing Director
- CSL Enters Licensing Agreement with Arcturus Therapeutics for Next Generation mRNA Vaccine Technology
- CSL Vifor Market Briefing
- Finalisation of Vifor Pharma Acquisition
Later from CSL
- Market Update
- CSL Statutory Accounts for the Full Year Ended 30 June 202
- CSL Results Announcement
- Top-line Results from the Phase 3 AEGIS-II Trial
- Half Year Results Announcement
Follow CSL into a list and get an email when it puts out news.
Follow CSL